EA201170647A1 - Пептиды-агонисты crhr2 и их использование - Google Patents

Пептиды-агонисты crhr2 и их использование

Info

Publication number
EA201170647A1
EA201170647A1 EA201170647A EA201170647A EA201170647A1 EA 201170647 A1 EA201170647 A1 EA 201170647A1 EA 201170647 A EA201170647 A EA 201170647A EA 201170647 A EA201170647 A EA 201170647A EA 201170647 A1 EA201170647 A1 EA 201170647A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crhr2
relates
present
peptide agonists
new
Prior art date
Application number
EA201170647A
Other languages
English (en)
Inventor
Роналд В. Свансон
Найджел П. Шэнкли
Вероника Морено
Питер Дженго
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201170647A1 publication Critical patent/EA201170647A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

Настоящее изобретение относится к новым пептидам, селективным агонистам рецептора кортикотропин-рилизинг-гормона 2 типа (CRHR2) и содержащим их композициям для лечения, снижения интенсивности проявления или замедления развития патологических состояний сердечно-сосудистой системы, включая, помимо прочего, сердечную недостаточность. Новый пептид-агонист предпочтительно содержит модификации, включающие пэгилированные пептиды. Кроме того, настоящее изобретение относится к способам лечения и профилактики заболеваний или нарушений, опосредованных активностью CRHR2.
EA201170647A 2008-11-04 2009-11-04 Пептиды-агонисты crhr2 и их использование EA201170647A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11123308P 2008-11-04 2008-11-04
US17889009P 2009-05-15 2009-05-15
PCT/US2009/063276 WO2010053990A2 (en) 2008-11-04 2009-11-04 Crhr2 peptide agonists and uses thereof

Publications (1)

Publication Number Publication Date
EA201170647A1 true EA201170647A1 (ru) 2011-12-30

Family

ID=41509080

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170647A EA201170647A1 (ru) 2008-11-04 2009-11-04 Пептиды-агонисты crhr2 и их использование

Country Status (20)

Country Link
US (1) US10040838B2 (ru)
EP (1) EP2362881B1 (ru)
JP (1) JP2012508014A (ru)
KR (1) KR20110091720A (ru)
CN (1) CN102272151B (ru)
AU (1) AU2009313619A1 (ru)
BR (1) BRPI0921640A2 (ru)
CA (1) CA2742710A1 (ru)
CO (1) CO6341479A2 (ru)
CR (1) CR20110305A (ru)
EA (1) EA201170647A1 (ru)
EC (1) ECSP11011099A (ru)
ES (1) ES2723098T3 (ru)
IL (1) IL212685A0 (ru)
MX (1) MX2011004718A (ru)
NI (1) NI201100087A (ru)
NZ (1) NZ592670A (ru)
SG (1) SG171957A1 (ru)
WO (1) WO2010053990A2 (ru)
ZA (1) ZA201104160B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201170647A1 (ru) 2008-11-04 2011-12-30 Янссен Фармацевтика Нв Пептиды-агонисты crhr2 и их использование
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
AU2013221615B2 (en) 2012-02-14 2018-02-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0747485B1 (en) 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
JP4472256B2 (ja) 2001-03-15 2010-06-02 リサーチ ディベロップメント ファンデーション ウロコルチンｉｉｉ及びその利用
CA2448022C (en) 2001-05-21 2013-11-12 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
US7144985B2 (en) * 2001-12-03 2006-12-05 Metabolex, Inc. Methods and reagents for diagnosis and treatment of diabetes
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
CN100480267C (zh) * 2002-01-16 2009-04-22 宝洁公司 促肾上腺皮质激素释放因子2受体激动剂
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
SG176455A1 (en) 2003-10-09 2011-12-29 Ambrx Inc Polymer derivatives
US20080261863A1 (en) * 2004-06-12 2008-10-23 Bayer Pharmaceuticals Corp Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US20100249027A1 (en) 2007-05-25 2010-09-30 William Henry Crf conjugates with extended half-lives
RU2010114038A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза
CA2699066A1 (en) 2007-09-14 2009-03-19 Basf Plant Science Gmbh Plants having increased yield-related traits and a method for making the same comprising expression of a growth-regulating factor (grf) polypeptide
EA201170647A1 (ru) 2008-11-04 2011-12-30 Янссен Фармацевтика Нв Пептиды-агонисты crhr2 и их использование
CN102781965A (zh) 2009-10-06 2012-11-14 安吉奥开米公司 用于转运治疗剂的组合物和方法
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
WO2013012866A1 (en) 2011-07-18 2013-01-24 The United States Of America As Represented By The Secretary. Methods and compositions for inhibiting polyomavirus-associated pathology

Also Published As

Publication number Publication date
EP2362881A2 (en) 2011-09-07
NZ592670A (en) 2013-01-25
ECSP11011099A (es) 2011-07-29
CA2742710A1 (en) 2010-05-14
US10040838B2 (en) 2018-08-07
BRPI0921640A2 (pt) 2019-09-24
WO2010053990A2 (en) 2010-05-14
NI201100087A (es) 2011-10-25
EP2362881B1 (en) 2019-03-13
CN102272151B (zh) 2014-08-20
IL212685A0 (en) 2011-07-31
WO2010053990A3 (en) 2010-07-01
JP2012508014A (ja) 2012-04-05
CO6341479A2 (es) 2011-11-21
CN102272151A (zh) 2011-12-07
MX2011004718A (es) 2011-07-28
US20100130424A1 (en) 2010-05-27
ZA201104160B (en) 2012-11-28
KR20110091720A (ko) 2011-08-12
ES2723098T3 (es) 2019-08-21
CR20110305A (es) 2011-11-10
SG171957A1 (en) 2011-07-28
AU2009313619A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
Yuan et al. Role of Nrf2 in cell senescence regulation
Okajima et al. Regulation of inflammatory responses by sensory neurons: molecular mechanism (s) and possible therapeutic applications
Wang et al. Endothelium-derived 5-methoxytryptophan is a circulating anti-inflammatory molecule that blocks systemic inflammation
Lu et al. The expression of angiotensin-converting enzyme 2–angiotensin-(1–7)–Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201291234A1 (ru) Аналоги глюкагона
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
EA201170647A1 (ru) Пептиды-агонисты crhr2 и их использование
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA201290027A1 (ru) Ацилированные аналоги глюкагона
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200971053A1 (ru) Способы лечения кожных язв
EA202091230A3 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
ME00356B (me) Novi peptidi koji se vezuju za receptor eritropoietina
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA202091105A1 (ru) Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1)
EA201170847A1 (ru) Тиазолопиридиновые соединения, регулирующие сиртуин
EA201171361A1 (ru) Ингибиторы внешнего медуллярного калиевого канала почек
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
EA201100609A1 (ru) Способы лечения воспаления